On May 22nd, at 21:00, the international academic journal The Lancet published the results of the world’s first recombinant adenovirus type 5 vector new corona vaccine Phase I clinical trial, the paper’s author is Chen Wei, a member of the Chinese Academy of Engineering. According to the paper, studies have shown that the aforeid Ad5-based new coronavaccine, which shows immunogenicity and human tolerance 28 days after being vaccinated against volunteers.
In healthy adults, the body fluid immune response to SARS-CoV-2 peaked on the 28th day after vaccination, and the rapid specific T-cell response was recorded from the 14th day after vaccination.
Earlier, at noon on May 22nd, the international academic journal The Lancet told The News that it had confirmed its acceptance of a research paper by Chen Wei of the Chinese Academy of Engineering and the Institute of Bioengineering of the Institute of Military Medicine of the Academy of Military Sciences on the results of clinical trials of the new crown vaccine;
On March 16, the recombinant new crown vaccine developed by Chen Wei’s team passed the clinical study registration review, and at 20:18 on the same day, it was approved to enter clinical trials.
108 volunteers in Phase I clinical trials and 508 volunteers in Phase 2 clinical trials.
The first 108 volunteers have been vaccinated since March 16. They were then placed in the Wuhan Secret Service Sanatorium for intensive isolation and observation.
From March 31st, the first volunteers ended their intensive isolation and returned home. The volunteers collected blood samples on the 28th, 3rd, and 6th months after vaccination.
The second phase of the vaccine, which was launched on April 12, is the only new coronavirus vaccine in the world to enter Phase II clinical trials, according to the Beijing Daily. On April 25, Academician Chen Wei revealed at the “National Children’s Vaccination Day Theme Live Event” that 508 volunteers from the second phase of the new corona vaccine clinical trial have been injected and are in the observation period, and if all goes well, they will be blinded in May.
Chen Wei said she led her team to start vaccine research in the first place since China shared the genetic virus sequence strains isolated by scientists with WHO. On March 16, the first phase of the adenovirus vector recombinant neo-coronavirus vaccine was officially approved and the first volunteer was injected on the same day. Vaccine development went well after that, with statistical data on safety for 7 and 14 days. On this basis, the above-mentioned vaccine into Phase II clinical trials.